China US-headquartered global genomic sequencing giant Illumina has endured a tough few years. However, now that various legal wrangles over its acquisition of cancer diagnostics developer GRAIL have been largely resolved and with a new global CEO in place, the firm has outlined a new growth strategy and is predicting high…
China Drawing on a wealth of Big Pharma experience, Jenny Zheng now leads China operations for Illumina, a global leader in genomics, specialising in DNA sequencing technology that drives innovation in healthcare, research, and personalised medicine. Illumina continues to see China as a crucial part of its global strategy due to…
USA Illumina’s newly appointed CEO, Jacob Thaysen, will take the reins of the gene sequencing giant at the end of September. Falling heir to the difficulties that have plagued Illumina since its botched acquisition of cancer blood test maker Grail, Thaysen will have to confront the company’s legal tangles with the…
See our Cookie Privacy Policy Here
